Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Lung Neoplasms × AMG 757 × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 2 Expanded_access 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Lung Neoplasms 1 Bites and Stings 1

Interventions

trilaciclib 1 taletrectinib 1 lazertinib 1 dabrafenib 1 capmatinib 1 brigatinib 1 Suspensions 1 Powders 1 Paclitaxel 1 BID protein, human 1 AMG 757 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Amgen

Approved for marketing

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡